Market Report Source

Overview

The rising prevalence of obesity is a growing problem in developed countries, with 32% of Americans and 17% of EU residents considered obese in 2008. The condition is associated with a range of severe co-morbidities, the most significant of which include asthma, cardiovascular disease, cancer, diabetes, hypertension and kidney disease. Obesity-related treatments cost healthcare payors billions of dollars each year, and the market for medications is steadily expanding as incidence of obesity continues to increase.

Stringent regulations have restricted the amount of medications currently available, however many currently marketed products are failing to meet consumer needs. ‘Obesity Drug Markets in the US and EU: Analysis of product pipelines and competitive environment’ is a new report published by Business Insights that explores the dynamics and drivers of the market for current and emerging obesity treatments. This report evaluates the performances and attributes of currently marketed products and highlights the most effective strategies for securing future success in this therapeutic area. The potential of leading obesity drug candidates is assessed and over 100 compounds are identified across pre-clinical, Phase I, Phase II and Phase III development.

Forecasts of future sales are also provided, based upon trends in obesity drug usage, projected prevalence rates and the approval potential of emerging products. Explore the latest trends and innovations in obesity treatments, assess the performances of currently marketed medications and evaluate the potential of leading pipeline candidates with this report

Table of Contents

Chapter 1 The large and growing obesity problem 18
Summary 18
A potentially life threatening medical condition 19
Levels of obesity 19
Overweight 20
Obesity 20
Morbid obesity 20
Super obesity 21
Co-morbidities and mortality 22

• Arthritis 23


• Asthma 23


• Cancer 24


• Cardiovascular disease and hypertension 25


• Dementia 26


• Depression 27


• Diabetes 27


• Kidney disease 27

Rising prevalence of obesity 28
Trends by sub-population 31

• United States 31


• Europe 31

Obesity in children and adolescents 33
Heavy social and economic impact 35

• Cost burden 35


• Social effects 36


• Societal and other effects 38

Medical overview of obesity 39
Pathogenesis of obesity 39
Physiological factors 40
Genetic factors 41
Environmental factors 42
Lifestyle factors 43
Psychological factors 44
Societal trends 46
Obesity as a component of metabolic syndrome 47
Conclusion 48

Chapter 2 Current approaches to obesity management 50
Summary 50
Background 51
Diet and exercise programs 52

Dieting 52

• Types of programs 53


• Patient volumes 54

Exercise 54

• Types of programs 54


• Patient volumes 55

OTC weight loss supplements 56

• Types of products 56


• Patient volumes 57

Pharmaceutical options 58

• Types of medications 58


• Patient volumes 59

Surgical intervention 60

• Types of procedures 61


• Patient volumes 63

Comparison of options 64
Safety 65
Efficacy 66
Cost 67

• Insurance reimbursement 67

Unmet needs 69
Conclusion 70

Chapter 3 Pharmaceutical options for treatment of obesity 72
Summary 72
Leading prescription medications 73
Meridia 74
Xenical 77
Acomplia 80
Others 83
OTC medicines 85
Alli 86
Comparison of pharmaceutical options 89
Safety 89
Efficacy 91
Cost 92

• Insurance reimbursement 93

Conclusion 95

Chapter 4 The obesity drug pipeline 98
Summary 98
Introduction 99
Pre-clinical testing 99
Phase I testing 116
Phase II testing 116
Phase III testing 117
Leading obesity drug candidates 118
Lorcaserin hydrochloride 118
Lepislim 120
Taranabant 120
Contrave 121
CP-945,598 123
Qnexa 123
Discontinued obesity drug candidates 125
Conclusion 132

Chapter 5 Market forecasts 134
Summary 134
Introduction 135
Current sales levels 135
United States 137
Europe 138
Five year forecasts 139
United States 141
Europe 143
Conclusion 145

Index 146

List of Figures

Figure 1.1: Rates of obesity and overweight in the US, 1980–2006 29
Figure 1.2: Rates of obesity and overweight in Europe, 1980–2006 30
Figure 2.3: Comparison of safety, efficacy and cost of obesity management approaches 64
Figure 3.4: Comparison of safety, efficacy and cost of pharmaceutical options for obesitymanagement 89
Figure 4.5: Comparison of leading obesity drug candidates, 2008 119
Figure 5.6: Obesity medication sales in the US and EU, 2006 and 2007 136
Figure 5.7: Obesity medication sales by region, 2007 137
Figure 5.8: Obesity medication sales in the US and EU, 2008–2013 140
Figure 5.9: Total obesity medication sales by region, 2008–2013 141

List of Tables

Table 1.1: Proportion of cancers related to obesity 24
Table 1.2: Prevalence of adult overweight and obesity by country, 2003 32
Table 2.3: US and EU patient caseloads for leading obesity management approaches, 2007–12
(millions of persons) 52
Table 2.4: Safety risks associated with obesity management approaches 65
Table 2.5: Comparative efficacy of obesity management approaches 66
Table 3.6: Safety risks associated with leading obesity medications 90
Table 3.7: Safety risks associated with leading obesity management approaches 92
Table 3.8: US cost comparison for leading obesity medications, 2008 93
Table 4.9: Pharmaceutical pipeline for obesity medications 101
Table 4.10: Discontinuations of obesity drug programs 126
Table 5.11: US sales of obesity medications, 2006 and 2007 138
Table 5.12: European sales of obesity medications, 2006 and 2007 139
Table 5.13: US sales of obesity medications in $m, 2008–2012 142
Table 5.14: European sales of obesity medications in $m, 2008–2012 143